How to buy Biohaven Pharmaceutical Holding Company stock | $87

Biohaven Pharmaceutical Holding Company Ltd is a biotechnology business based in the US. Biohaven Pharmaceutical Holding Company shares (BHVN) are listed on the NYSE and all prices are listed in US Dollars. Biohaven Pharmaceutical Holding Company employs 825 staff and has a trailing 12-month revenue of around 0.00.

Biohaven Pharmaceutical Holding Company stock price (NYSE: BHVN)

Use our graph to track the performance of BHVN stocks over time.

Biohaven Pharmaceutical Holding Company shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$87.00
52-week range	$57.66 - $132.91
50-day moving average	$109.78
200-day moving average	$86.33
Wall St. target price	$118.45
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-9.14

Buy Biohaven Pharmaceutical Holding Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biohaven Pharmaceutical Holding Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biohaven Pharmaceutical Holding Company Ltd by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biohaven Pharmaceutical Holding Company price performance over time

Historical closes compared with the close of $87 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	-12.74%
3 months (2021-04-30)	15.85%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Biohaven Pharmaceutical Holding Company financials

Revenue TTM	$106.3 million
Gross profit TTM	$45.9 million
Return on assets TTM	-59.42%
Return on equity TTM	0%
Profit margin	0%
Book value	$2.09
Market capitalisation	$8.2 billion

TTM: trailing 12 months

Shorting Biohaven Pharmaceutical Holding Company shares

There are currently 4.8 million Biohaven Pharmaceutical Holding Company shares held short by investors – that's known as Biohaven Pharmaceutical Holding Company's "short interest". This figure is 21.3% down from 6.2 million last month.

There are a few different ways that this level of interest in shorting Biohaven Pharmaceutical Holding Company shares can be evaluated.

Biohaven Pharmaceutical Holding Company's "short interest ratio" (SIR)

Biohaven Pharmaceutical Holding Company's "short interest ratio" (SIR) is the quantity of Biohaven Pharmaceutical Holding Company shares currently shorted divided by the average quantity of Biohaven Pharmaceutical Holding Company shares traded daily (recently around 971842.28456914). Biohaven Pharmaceutical Holding Company's SIR currently stands at 4.99. In other words for every 100,000 Biohaven Pharmaceutical Holding Company shares traded daily on the market, roughly 4990 shares are currently held short.

However Biohaven Pharmaceutical Holding Company's short interest can also be evaluated against the total number of Biohaven Pharmaceutical Holding Company shares, or, against the total number of tradable Biohaven Pharmaceutical Holding Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biohaven Pharmaceutical Holding Company's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Biohaven Pharmaceutical Holding Company shares in existence, roughly 70 shares are currently held short) or 0.0881% of the tradable shares (for every 100,000 tradable Biohaven Pharmaceutical Holding Company shares, roughly 88 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biohaven Pharmaceutical Holding Company.

Find out more about how you can short Biohaven Pharmaceutical Holding Company stock.

Biohaven Pharmaceutical Holding Company share dividends

We're not expecting Biohaven Pharmaceutical Holding Company to pay a dividend over the next 12 months.

Biohaven Pharmaceutical Holding Company share price volatility

Over the last 12 months, Biohaven Pharmaceutical Holding Company's shares have ranged in value from as little as $57.66 up to $132.91. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Biohaven Pharmaceutical Holding Company's is 1.0082. This would suggest that Biohaven Pharmaceutical Holding Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Biohaven Pharmaceutical Holding Company overview

Biohaven Pharmaceutical Holding Company Ltd. , a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Frequently asked questions

What percentage of Biohaven Pharmaceutical Holding Company is owned by insiders or institutions?
Currently 12.384% of Biohaven Pharmaceutical Holding Company shares are held by insiders and 111.931% by institutions. How many people work for Biohaven Pharmaceutical Holding Company?
Latest data suggests 825 work at Biohaven Pharmaceutical Holding Company. When does the fiscal year end for Biohaven Pharmaceutical Holding Company?
Biohaven Pharmaceutical Holding Company's fiscal year ends in December. Where is Biohaven Pharmaceutical Holding Company based?
Biohaven Pharmaceutical Holding Company's address is: 215 Church Street, New Haven, CT, United States, 06510 What is Biohaven Pharmaceutical Holding Company's ISIN number?
Biohaven Pharmaceutical Holding Company's international securities identification number is: VGG111961055 What is Biohaven Pharmaceutical Holding Company's CUSIP number?
Biohaven Pharmaceutical Holding Company's Committee on Uniform Securities Identification Procedures number is: G11196105